Demand for weight-loss treatments is rising fast - and regulators risk patients’ health by not keeping pace.
Weight-loss drugs continue to grab headlines, some of the latest being that NHS eligibility is widening following new clinical evidence showing their role in reducing cardiovascular risk.
This potentially opens access to a further 1.2 million NHS patients with existing heart conditions over time.
A fundamental shift, these medicines are no longer being positioned purely as weight loss interventions but increasingly as part of long-term condition management and prevention.
The scale of the market already tells its own story. An estimated 4.9 million adults in Great Britain have recently used a drug to support weight loss or are interested in using one in the near future, according to analysis from University College London.
The weight management category is expanding rapidly, but it remains highly fragmented.
Alongside a small number of established providers, a long tail of digital-first and online operators has emerged, many moving quickly to meet consumer demand.
But the issue is not innovation or access.
Weight-loss drugs are prescription-only medicines often used by patients with complex health profiles. Yet the level of clinical oversight varies significantly depending on where and how patients access treatment.
In some cases, the process is robust and clinically led. At Well Pharmacy we offer a pharmacy-led weight-loss service across our 650 UK branches and online, with structured consultations, regular check-ins and clinical monitoring designed to ensure treatment is safe.
Whereas, in more worrying cases, access to these drugs can be reduced to a transactional interaction with limited verification, minimal checks and little ongoing support.
Weight management is not a one-off intervention. It requires appropriate patient selection, monitoring and support throughout the treatment journey, particularly when patients experience side effects or discontinue use.
Without that framework, there is a risk that outcomes are compromised and patient safety is not consistently protected. This is where community pharmacy should be playing a far more central role.
Pharmacy already operates at scale, supporting patients with long-term conditions every day. It combines accessibility with clinical expertise, and crucially, offers continuity of care.
Many of the patients now becoming eligible for weight management treatments are already known to pharmacy teams. They are collecting prescriptions, managing cardiovascular conditions and engaging regularly with healthcare professionals. There is an existing relationship.
Extending that into weight management would provide a more joined up, supported patient experience. And yet, much of the growth in this category is happening outside of that environment, with a rise in online supply routes that bypass appropriate clinical checks and, in some cases, involve unregulated and unsafe products.
The core issue is that the regulatory framework has not kept pace with the speed of market expansion. There is a clear case for introducing more consistent standards across the sector.
At a minimum, this should include a requirement for a meaningful consultation, whether face-to-face or via video, rather than relying solely on self-reported information.
There should also be clearer expectations around ongoing care. Basic health checks, such as blood pressure monitoring, routine follow up and structured clinical guidance, should form part of a standardised patient pathway.
This is not about limiting access. It is about ensuring that access is safe, appropriate and supported. There is also an opportunity to go further and formalise how these services are delivered.
As the NHS continues to prioritise prevention and community-based care, weight management could evolve into a commissioned pharmacy service, with defined clinical protocols, service specifications and funding attached to delivery.
This would bring structure and consistency to the category, while recognising the role pharmacy can play in managing growing demand outside of GP and hospital settings.
It would also help address the current imbalance, where large numbers of patients are accessing treatment privately, often without the same level of guidance or continuity of care.
Online services will continue to play an important role, but they must operate within a framework that ensures appropriate governance and patient protection.
The trajectory of this market is clear. Demand is rising, eligibility is expanding, and the role of these medicines in managing long-term conditions is becoming more established.
But without the right regulation in place, there is a risk that growth continues in a way that is inconsistent and, in some cases, insufficiently supported.
Community pharmacy has the infrastructure, the expertise and the patient relationships to deliver this service effectively.
The question is whether policy and regulation will evolve quickly enough to enable it.
Because if access is going to expand to millions more patients, the system delivering it must be built to match that scale, safely, consistently and with patient wellbeing at its centre.
(Jeremy Meader is chief wholesale officer, Bestway Healthcare)
